Ocular Therapeutix (OCUL) Misses Q1 EPS by 4c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ocular Therapeutix (OCUL) Reports First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for Treatment of Dry Eye Disease
May 12, 2020 7:13 AM EDTOcular Therapeutix, Inc. (NASDAQ: OCUL) today announced that it has dosed the first patients in its Phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED).
We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease, said Michael Goldstein, MD, MBA, Chief Medical Officer. We believe that the intracanalicular route of administration could provide key benefits in all ocular surface diseases but particularly in dry eye. The intracanalicular route allows for preservative-free delivery of a constant dose of cyclosporine, so it may be... More
